THE FUTURE IS HERE

Meet LINQ II[™]

Insertable Cardiac Monitoring System





Personalized for the patient's lifestyle and customized for the clinician's workflow.

Medtronic

THE Future Is here



Meet LINQ II[™] Insertable Cardiac Monitoring System



SIGNIFICANTLY REDUCING BURDEN ASSOCIATED WITH EPISODE REVIEW

UNMATCHED ACCURACY

- TruRhythm[™] Detection delivers the lowest published rate of AF false positives¹⁻⁴
- NEW Pause detection algorithm, NEW PVC detection algorithm and Brady/Tachy algorithms enhancements reduce false positives and alerts^{5,6}



REIMAGINED CONNECTIVITY

ENHANCING DISEASE MANAGEMENT AND IMPROVING PATIENT EXPERIENCE

- Increased disease management capabilities with 4.5-year longevity^{*7}, without sacrificing device size
- BlueSync[™] technology enables wireless secure communication, for an improved remote monitoring experience
- Two monitoring options to fit patient lifestyle: MyCareLink Heart[™] App and MyCareLink Relay[™] Home Communicator



STREAMLINED WORKFLOWS


DRIVING EFFICIENCIES AT EVERY STEP OF THE PATH TO DIAGNOSIS

- Remote programming may reduce patient office visits and non-actionable transmissions
- Efficient follow-up⁶ with full remote ECG access (without need for manual transmissions⁷) and smart memory management that reduces repetitive ECG⁸
- Exclusive Reveal LINQ[™] Mobile Manager enabling seamless device programming and remote monitoring enrollment
- BeConnected Patient Service and FocusOn[™] Monitoring and Triaging Service free up clinic time, enabling efficient patient management



GNIFICANTLY EDUCING BURDEN ASSOCIATED WITH EPISODE REVIEW.

The **TruRhythm[™] Detection** enables the lowest published rate of AF False positives.¹⁻⁴



When compared to other ICMs, LINQ II[™] provides up to:⁹

Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done. *Based on AF episodes ≥ 2 minutes and in known AF patients. % of false positives = (1 – episode PPV). AF episodes PPV may vary between gross and patient average.

† Confirm™ Rx with SharpSense™ technology & BIOMONITOR III have no published clinical evidence showing AF episode PPV or AF sensitivity.



Vs Confirm[™] RX

Vs BioMonitor[™] 2

Time savings are based on a clinic managing 100 ICMs with full-time employees (44 weeks/year, 40h/ week). Review time is estimated based on a known AF patient population.

NEW PAUSE DETECTION ALGORITHM



The Pause Detection algorithm reduces burden due to false detection by addressing low amplitude, electrical noise and loss of contact.³




*LINQ II[™] vs. Reveal LINQ[™] with TruRhythm[™]

NEW **PVC DETECTION** ALGORITHM



- The PVC Detection algorithm uses both R-R interval and morphology characteristics to distinguish a PVC beat from a normal beat.

• PVC count is presented in % of beats visible in the patient's Quick Look™ or Cardiac Compass[™]



OPTIMIZE WORKFLOW BY REDUCING FALSE POSITIVE AND ALERTS.^{5,6} **INDICATION-**BRADY **AND TACHY** BASED ALGORITHM NOMINAL **ENHANCEMENTS** SETTINGS

Reduces false pause detection by 79%*10




May help identify high-risk patients^{11,12}











ENHANCING DISEASE MANAGEMENT AND IMPROVING PATIENT EXPERIENCE.


Device longevity up to 4.5 years.

4.5-year^{7*} longevity allows for increased disease management capabilities without sacrificing device size.

BLUESYNC[™] TECHNOLOGY INSIDE

The BlueSync[™] technology inside LINQ II[™] enables secure, wireless communication via Bluetooth[®] Low Energy for an improved remote monitoring experience.





smartphones or tablets. High-Density Integrated Circuit

KEY

DESIGN


CHANGES

Bluetooth Low Energy Enabled to automatically and securely communicate with Bluetooth Low Energy

Reduces current drain for increased longevity.

Encryption Module Data are encrypted in the insertable cardiac monitor using NIST** standard encryption.

Two Monitoring options personalized for patient's lifestyle.



MyCareLink Heart[™] has been designed to enable:

- Patient Compliance. resulting in Increased Clinic Efficiencies¹³
- Patient Engagement, promoting Patient Satisfaction¹⁴
- Upgradeability, setting the Foundation for Future Technologies

Patients can use their smartphone or tablet to record symptoms and automatically transfer device data via the MyCareLink Heart[™] mobile app, even outside their home.

**NIST: National Institute of Standards and Technology



MyCareLink Relay[™] Home Communicator



MyCareLink Relay[™] offers an easy monitor alternative, designed for bedside use:

- No manual pairing required
- Requires little to no user interaction
- For patients who prefer not to or are unable to use a smartphone

An optional patient assistant can be provided to patients to mark symptoms as they happen.



STREAMLINED WORKFLOWS

DRIVING EFFICIENCIES AT EVERY STEP OF THE PATH TO DIAGNOSIS.



LINQ II[™] is the first ICM with **remote programming capability^{7*}:**


- Enables programming directly from clinic for all device parameters post-insertion
- Enables on-going programming optimization which reduces non-actionable transmissions
- May reduce patient office visits and scheduling challenges



CareLink[™]

Network





MyCareLink Heart[™] Mobile App or MyCareLink Relay[™] Home Communicator **LINQ II™** With BlueSync™ technology


*First CE-marked ICM with remote programming capabilities.

SMART MEMORY MANAGEMENT

Higher quality data provided through auto-transmission.

Up to 23 full ECG per day stored & transmitted.





Access to all stored full ECGS eliminates need for manual transmissions.^{5,7}



Reducing clinician burden


Reducing the need for patient compliance



DRIVING **EFFICIENCIES** AT EVERY STEP OF THE PATH TO DIAGNOSIS.

all from your tablet.





solution and answering device and monitoring questions.



better outcomes.

THE Future Is here



Meet LINQ II[™] Insertable Cardiac Monitoring System

REFERENCES

- 1. Nölker G, et al. J Cardiovasc Electrophysiol. 2016;27:1403-1410.
- 2. Confirm Rx[™] ICM DM3500 FDA Clearance Letter. 2017.
- 3. Biotronik BioMonitor™ 2 Technical Manual. 2017.
- 4. Pürerfellner H, et al. Europace. 2018;20:f321-f328.
- 5. Epstein AE, et al. J Am Coll Cardiol. 2013;61:e6-e75.
- 6. Alert Analysis for Reveal LINQ with TruRhythm and LINQ II. Medtronic data on file. 2020.
- 7. LNQ22 ICM Clinician Manual. M974764A001D.
- 8. Van Heel L, et al. Circulation. 2019;140:A11830.
- Rosemas S. AF Algorithm Clinic Efficiency. Medtronic data on file. April 2020. Based on Rogers J., et al. Circulation 140: A11947, Nölker 2016, Confirm Rx™ ICM DM3500 FDA Clearance Letter. 2017, Biotronik BioMonitor™ 2 Technical Manual 2017. Pürerfellner 2018
- 10. Medtronic data on file. 2019.
- 11. Penela D, et al. J Am Coll Cardiol. 2013;62:1195-1202.
- 12. Penela D, et al. Heart Rhythm. 2017;14:1864-1870.
- 13. Cronin EM, et al. Heart Rhythm. 2012;9:1947-1951.
- 14. Varma N. Cont Cardiol Educ. 2016;2:198-204.

BRIEF STATEMENT

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan[™] device, see the MRI SureScan[™] technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on www.manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat[®] Reader with the browser.

Photo credit: Getty Images, Adobe Stock.



Europe

Medtronic International Trading Sårl. Route du Molliau 31 Case postale 1131 Tolochenaz Switzerland www.medtronic.eu Tel: +41 (0)21 802 70 00 Fax: +41 (0)21 802 79 00

UC202107685 EE © Medtronic 2020. All rights reserved. Printed in Europe.

medtronic.eu